Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction

(2016) Kenneth B. Margulies et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure

(2016) Kristian B. Filion et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glucagon-like peptide-1 regulates calcium homeostasis and electrophysiological activities of HL-1 cardiomyocytes

(2016) Jen-Hung Huang et al.   PEPTIDES

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

(2016) Ling Li et al.   BMJ-British Medical Journal

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

(2016) Ling Li et al.   BMJ-British Medical Journal

Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

(2015) Wei Ren Chen et al.   AMERICAN HEART JOURNAL

Cardiovascular Actions of Incretin-Based Therapies

(2014) John R. Ussher et al.   CIRCULATION RESEARCH

GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody

(2014) Charles Pyke et al.   ENDOCRINOLOGY

A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)

(2014) Anders Jorsal et al.   BMJ Open

Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties

(2013) Daniela Dobre et al.   EUROPEAN JOURNAL OF HEART FAILURE

EAE/ASE Recommendations for Image Acquisition and Display Using Three-Dimensional Echocardiography

(2012) R. M. Lang et al.   European Heart Journal-Cardiovascular Imaging

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

(2010) Mads Halbirk et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

(2010) Michael Böhm et al.   LANCET

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Reproducibility in echocardiographic assessment of the left ventricular global and regional function, the HUNT study

(2009) A. Thorstensen et al.   European Journal of Echocardiography

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

(2008) M. R. MacDonald et al.   EUROPEAN HEART JOURNAL

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

(2008) Kim Fox et al.   LANCET